Bio-Rad Laboratories is still considering potential acquisition opportunities but is maintaining what its calls a “disciplined approach” in spending its cash holdings of $246 million, company officials said last week.
 
The firm has not been as aggressive as some of its chief competitors — namely Qiagen and Invitrogen — in the M&A market over the past couple of years, but each quarter analysts quiz company officials about the firm’s acquisition plans.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.